SIGA Technologies Stock News: SIGA rallies on WHO monkeypox declaration
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- SIGA stock is up 26% in Monday's premarket.
- WHO declares Monkeypox a public health emergency of global concern.
- SIGA stock rallying as the company has a monkeypox treatment.
SIGA stock is up again as monkeypox treatment stocks continue to see renewed interest as the monkeypox outbreak shows no signs of abating. SIGA stock advanced 43% in May as monkeypox concerns grew, and SIGA has remained elevated ever since.
SIGA stock news
The reason for Monday's premarket gain is because the World Health Organisation (WHO) has declared monkeypox a health emergency of global concern. SIGA Technologies has a treatment for smallpox named TPOXX, which was approved for use in the US by the FDA in 2018. In January the European equivalent gave TPOXX authorization for monkeypox. SIGA Technologies said two weeks ago it had received orders totaling $56 million so far this year for TPOXX. Now with this latest declaration from the WHO, monkeypox stocks are once again rising, and SIGA stock is set to gain.
“We have an outbreak that has spread around the world rapidly through new modes of transmission, about which we understand too little, and which meets the criteria” for a public health emergency, the Director-General of the WHO, Tedros Adhanom, said.
Other stocks of note to watch in the same space are Tonix Pharma (TNXP), GeoVax Labs (GOVX) and Emergent Bio (EBS).
SIGA daily chart
Also read: Polestar (PSNY) stock falls sharply as news flow dries up
- SIGA stock is up 26% in Monday's premarket.
- WHO declares Monkeypox a public health emergency of global concern.
- SIGA stock rallying as the company has a monkeypox treatment.
SIGA stock is up again as monkeypox treatment stocks continue to see renewed interest as the monkeypox outbreak shows no signs of abating. SIGA stock advanced 43% in May as monkeypox concerns grew, and SIGA has remained elevated ever since.
SIGA stock news
The reason for Monday's premarket gain is because the World Health Organisation (WHO) has declared monkeypox a health emergency of global concern. SIGA Technologies has a treatment for smallpox named TPOXX, which was approved for use in the US by the FDA in 2018. In January the European equivalent gave TPOXX authorization for monkeypox. SIGA Technologies said two weeks ago it had received orders totaling $56 million so far this year for TPOXX. Now with this latest declaration from the WHO, monkeypox stocks are once again rising, and SIGA stock is set to gain.
“We have an outbreak that has spread around the world rapidly through new modes of transmission, about which we understand too little, and which meets the criteria” for a public health emergency, the Director-General of the WHO, Tedros Adhanom, said.
Other stocks of note to watch in the same space are Tonix Pharma (TNXP), GeoVax Labs (GOVX) and Emergent Bio (EBS).
SIGA daily chart
Also read: Polestar (PSNY) stock falls sharply as news flow dries up
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.